C
Carlo M. Croce
Researcher at Ohio State University
Publications - 1156
Citations - 199822
Carlo M. Croce is an academic researcher from Ohio State University. The author has contributed to research in topics: microRNA & Cancer. The author has an hindex of 198, co-authored 1135 publications receiving 189007 citations. Previous affiliations of Carlo M. Croce include University of Nebraska Medical Center & University of California, Los Angeles.
Papers
More filters
Journal Article
Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
Tamotsu Kuroki,Francesco Trapasso,Sai Yendamuri,Ayumi Matsuyama,Hansjuerg Alder,Masaki Mori,Carlo M. Croce +6 more
TL;DR: The findings suggest that epigenetic silencing of RASSF1A gene expression by promoter hypermethylation could play an important role in primary esophageal squamous cell carcinogenesis.
Book ChapterDOI
Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy
TL;DR: TRNA-derived small RNAs (tsRNA) have been found to be frequently dysregulated in cancer and can interact with DNA and histone methylation machinery, suggesting a role in the pretranscriptional regulation of gene expression.
Journal ArticleDOI
WWOX expression in different histologic types and subtypes of non-small cell lung cancer.
Valentina Donati,Gabriella Fontanini,Matteo Dell'Omodarme,Maria Cristina Prati,Simona Nuti,Marco Lucchi,Alfredo Mussi,Muller Fabbri,Fulvio Basolo,Carlo M. Croce,Rami I. Aqeilan +10 more
TL;DR: The results suggest that the loss of WWOX expression plays different roles in tumorigenesis of distinct histotypes and subtypes of NSCLC and is related to high aggressiveness (G3; high proliferating activity) of tumors.
Journal ArticleDOI
Bortezomib treatment sensitizes oncolytic HSV-1 treated tumors to NK cell immunotherapy
Ji Young Yoo,Alena Cristina Jaime-Ramirez,Chelsea Bolyard,Hongsheng Dai,Tejaswini Nallanagulagari,Jeffrey Wojton,Brian Hurwitz,Theresa Relation,Tae Jin Lee,Michael T. Lotze,Jun Ge Yu,Jianying Zhang,Carlo M. Croce,Jianhua Yu,Michael A. Caligiuri,Matthew O. Old,Balveen Kaur +16 more
TL;DR: This study provides a significant rationale for triple combination therapy with bortezomib, oHSV, and NK cells to improve efficacy, in glioblastoma patients.